Brodalumab, a human monoclonal immunoglobulin G antibody approved for treating psoriasis vulgaris, psoriatic arthritis, pustular psoriasis, and psoriatic erythroderma, has a high affinity for IL‐17RA.[47] SSc DFs were pretreated with fully human anti‐IL‐17RA monoclonal antibody (anti‐IL‐17RA mAb) or PBS, followed by rChi3L1 treatment (Figure6A). The gene discussed is IL17RA; the disease is systemic sclerosis.